NEULANDLAB

Neuland Laboratories Ltd.

NSE: NEULANDLAB

BSE: 524558

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

23,995.00+1040.0 (+4.53%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

94.9 / 100

Value Score

9.6 / 100

Price Momentum Score

98.2 / 100

QVM Score

85.2 / 100

Key Metrics

Market Cap

30785.60

P/E (TTM)

61.85

P/B

16.42

P/S (TTM)

12.98

EV/EBITDA

52.87

CAPE (5Y)

119.28

ROE (TTM)

21.42

ROCE (TTM)

25.41

ROA (TTM)

14.25

Avg 3Y ROE

22.10

Earnings 3Y CAGR

32.20

Sales 3Y CAGR

21.18

Sales 5Y CAGR

20.53

Debt/Equity

0.16

Consensus TP

24110.00

Strong Buy %

50.00

Promoter Holding

32.62

Pledged %

2.29

Stock Analysis

Fundamental analysis overview of Neuland Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 98.2 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

98.2 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 9.54% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and improving ROE

The company reported strong ROE of 21.42% for 12-month ended 30 Jun 2026 and ROE improved by 289 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 24.22% for 12-month ended 30 Jun 2026 and operating margin improved by 1181 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 78.33% for 12-month ended 30 Jun 2026 and the growth was 67.74 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 78.33

-99.6111701.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 182.59% for 12-month ended 30 Jun 2026 and the growth was 175.39 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.16 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.06 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 7 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 61.85 indicates that the stock is expensive on a standalone basis and is at a 94.62% premium to industry median P/E

What is P/E Ratio?

Median: 31.78

Value 61.85

-0.96721.13

Low dividend yield

The company has a low dividend yield of 0.14%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 52.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

52.3 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Neuland Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Neuland Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Neuland Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	36.20	36.27	36.25	36.25	36.22	36.22	36.22	36.22	36.22	36.22	36.22	36.14	36.14	36.03	35.97	32.80	32.74	32.72	32.64	32.68	32.68	32.68	32.64	32.63	32.63	32.62
Indian Promoter	36.20	36.27	36.25	36.25	36.22	36.22	36.22	36.22	36.22	36.22	36.22	36.14	36.14	36.03	35.97	32.80	32.74	32.72	32.64	32.68	32.67	32.67	32.64	32.63	32.63	32.62
Foreign Promoter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	33.84	29.60	20.23	23.02	22.51	19.93	21.68	23.38	23.59	23.84	24.70	24.71	25.63	27.35	28.96	29.12	31.38	32.51	33.24	33.35	33.48	33.66	34.54	35.61	36.30	37.59
Mutual Funds / UTI	2.17	4.15	2.85	2.68	0.87	0.04	0.79	0.79	0.79	0.79	0.79	0.79	0.99	1.57	1.94	1.83	3.88	4.07	4.04	6.29	7.43	7.66	9.78	10.39	11.35	12.66
FI/Bank/Insurance	0.24	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.57	0.96	1.40	1.26	1.18	1.30	1.29
Govt	-	-	-	-	-	-	-	-	-	-	-	0.46	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40	-	-	-
FII	26.97	20.79	12.78	15.88	17.19	15.49	16.01	17.19	17.19	17.37	17.68	17.70	18.14	20.19	21.57	22.69	24.43	25.72	26.46	23.86	22.12	21.69	20.60	20.90	20.46	21.08
Other Institutions	4.47	4.47	4.64	4.47	4.47	4.42	4.90	5.41	5.61	5.69	6.22	5.75	6.11	5.19	5.05	4.19	2.66	2.32	1.94	2.23	2.58	2.51	2.51	3.15	3.19	2.57
Non-Institution	29.96	34.12	43.52	40.73	41.27	43.85	42.10	40.40	40.19	39.94	39.08	39.15	38.23	36.62	35.07	38.08	35.88	34.76	34.11	33.97	33.84	33.67	32.81	31.76	31.07	29.79
Bodies Corporate	-	-	4.75	4.68	4.49	4.18	5.38	4.54	4.55	4.32	3.80	5.65	5.22	4.74	4.45	6.62	5.18	5.11	5.06	5.34	5.45	5.61	5.56	5.03	4.85	4.67
Others (incl. Retail) No. of shareholders	29.96 11,488	34.12 12,677	38.77 18,532	36.05 19,681	36.78 22,133	39.67 34,619	36.72 33,940	35.86 32,039	35.64 31,877	35.62 31,579	35.28 30,203	33.50 29,267	33.01 26,553	31.88 24,785	30.62 26,349	31.46 27,155	30.70 28,031	29.65 28,482	29.05 33,745	28.63 38,375	28.39 38,389	28.06 41,456	27.25 43,311	26.73 45,091	26.22 45,279	25.12 43,274

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Smallcap 50	2.12%	21 / 49
2	Nifty Smallcap 250	0.77%	25 / 249
3	Nifty 500	0.08%	222 / 499
4	Nifty Total Market	0.08%	227 / 749

Prominent Investor Holdings

Vijay Kishanlal Kedia

Jun 2026

1.01%

₹ 312 Cr

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Neuland Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Nirupama Sundar Employees Immediate Relative	December-2023	Market Sale (Disposal) 5th Dec 2023	0.00 %	₹ 5,375.32	500.00	₹ 26.88 lac
Payal Gupta Employees Immediate Relative	September-2022	Market Purchase (Acquisition) 30th Sep 2022	0.00 %	₹ 1,278.12	1.27 k	₹ 16.19 lac
Nirupama Sundar Employees Immediate Relative	September-2022	Market Purchase (Acquisition) 1st Sep 2022	0.00 %	₹ 1,154.54	900.00	₹ 10.39 lac
GANNABATHULA VEERAVENKATA SATYANARAYANAMURTY Promoter Group	February-2021	Market Sale (Disposal) 12th Feb 2021	0.22 %	₹ 1,930.77	650.00	₹ 12.55 lac
GANNABATHULA VENKATA KRISHNA RAMA RAO Promoter	February-2021	Market Sale (Disposal) 12th Feb 2021	0.34 %	₹ 1,950.97	1.15 k	₹ 22.44 lac
SRINIVASA KRISHNA MOHAN DAVULURI Designated Person	February-2021	Market Sale (Disposal) 10th Feb 2021	0.01 %	₹ 1,687.75	1.00 k	₹ 16.88 lac
GANNABATHULA VEERAVENKATA SATYANARAYANAMURTY Promoter Group	February-2021	Market Sale (Disposal) 9th Feb 2021	0.23 %	₹ 1,566.18	850.00	₹ 13.31 lac
GANNABATHULA VENKATA KRISHNA RAMA RAO Promoter	February-2021	Market Sale (Disposal) 9th Feb 2021	0.34 %	₹ 1,566.18	850.00	₹ 13.31 lac

Corporate Actions

History of Neuland Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 34/share
Record date: 24th Jul 2026Ex-date: 24th Jul 2026
Announced on: 12th May 2026
Dividend₹ 12/share
Record date: 18th Jul 2025Ex-date: 18th Jul 2025
Announced on: 15th May 2025
Dividend₹ 14/share
Record date: 12th Jul 2024Ex-date: 12th Jul 2024
Announced on: 10th May 2024
Dividend₹ 10/share
Record date: 11th Jul 2023Ex-date: 11th Jul 2023
Announced on: 11th May 2023
Dividend₹ 5/share
Record date: 15th Jul 2022Ex-date: 14th Jul 2022
Announced on: 10th May 2022

Company Profile

Overview of Neuland Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical...

Key personnel

Mr. Davuluri Saharsh Rao

Chief Executive Officer, Managing Director

Mr. Abhijit Majumdar

Chief Financial Officer

Dr. Sharadsrikar V. (Sharad) Kotturi

Chief Scientific Officer

Ms. Sarada Bhamidipati

Compliance Officer, Company Secretary

Mr. Ashutosh Kumar Sinha

Chief Quality Officer

Mr. Diwakar Pingle

Managing Director

Dr. Davuluri Rama Mohan RaoD

Executive Chairman of the Board

Mr. Davuluri Sucheth RaoD

Executive Vice Chairman of the Board

View all

Incorporated on

07 Jan 1984

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

2,188

IPO date

18 Apr 1994

Free Float

79,88,464

Website

https://www.neulandlabs.com/

Phone no.

+914030211600

Address

11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-, III, Road No. 82, Jubilee Hills, HYDERABAD, 500033, India

Frequently Asked Questions

What is the current share price of Neuland Laboratories Ltd.?

The current share price of Neuland Laboratories Ltd. is ₹ 23,995.00 as of 8 Sep 2026.

What is the market capitalisation of Neuland Laboratories Ltd.?

The market capitalisation of Neuland Laboratories Ltd. stands at ₹ 30,785.60 Cr.

What is the PE ratio of Neuland Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Neuland Laboratories Ltd. is 61.85 as of the latest trailing twelve months data.

What is the ROE and ROCE of Neuland Laboratories Ltd.?

Neuland Laboratories Ltd. has a Return on Equity (ROE) of 21.42% and a Return on Capital Employed (ROCE) of 25.41% as per the latest financial reports.

What is the 52-week high and low of Neuland Laboratories Ltd.?

The 52-week high of Neuland Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Neuland Laboratories Ltd.?

The dividend yield of Neuland Laboratories Ltd. is 0.14% based on the current market price.

What is the FII and DII holding in Neuland Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 21.08%, Domestic Institutional Investors (DII) hold 13.95% and retail/public investors hold 25.12% of Neuland Laboratories Ltd. shares.

What sector does Neuland Laboratories Ltd. belong to?

Neuland Laboratories Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Neuland Laboratories Ltd. with a consensus target price of ₹ 24,110.00, implying 0.48% upside from current levels.

What is the beta of Neuland Laboratories Ltd.?

The beta of Neuland Laboratories Ltd. is 0.88, indicating its price volatility relative to the broader market. Over the past 1 year, Neuland Laboratories Ltd. has delivered an absolute return of 74.89%.

What is the RSI of Neuland Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Neuland Laboratories Ltd. is 67.18, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Neuland Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Neuland Laboratories Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Corporate Actions

Holdings and Presence